Literature DB >> 11698656

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.

J G Garcia-Lerma1, S Nidtha, K Blumoff, H Weinstock, W Heneine.   

Abstract

Transmission of HIV-1 with reduced susceptibility to antiretroviral drugs raises public health concerns. Through surveillance of drug-resistant HIV-1 in 603 treatment-naive, recently diagnosed HIV-1-infected persons, we identified a distinct group of viruses that have mutations at codon 215 of the reverse transcriptase (RT) gene that are different from either the wild-type (WT) T or the zidovudine (AZT)-selected T215Y/F. These mutations included 215D/C/S and were found in 20 patients (3.3%). The 215D, 215C, and 215S mutations differ from 215Y by a 1-nt change compared with 2 nt for the WT T215 and likely represent revertants of 215Y. These viruses all were found to have WT susceptibility to AZT, and all replicated efficiently as WT HIV-1(T215). However, differences in fitness among HIV-1(215D), HIV-1(215C), and HIV-1(215S) were seen when RT backgrounds were changed, demonstrating a role of the RT background in the selection of these revertants. In vitro selection with AZT showed that HIV-1(215D) and HIV-1(215C) acquired 215Y more rapidly than did WT HIV-1(T215), likely reflecting the need for only 1-nt change to evolve to 215Y. Our study demonstrates that HIV-1 with unusual mutations at codon 215 replicate efficiently, have WT susceptibility, and are commonly found in treatment-naive persons. The increased ability for selecting resistance mutations defines this class of WT HIV-1 and highlights the higher potential of these viruses to compromise the efficacy of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698656      PMCID: PMC61140          DOI: 10.1073/pnas.241300698

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.

Authors:  F Brun-Vézinet; C Boucher; C Loveday; D Descamps; V Fauveau; J Izopet; D Jeffries; S Kaye; C Krzyanowski; A Nunn; R Schuurman; J M Seigneurin; C Tamalet; R Tedder; J Weber; G J Weverling
Journal:  Lancet       Date:  1997-10-04       Impact factor: 79.321

2.  Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

Authors:  F M Hecht; R M Grant; C J Petropoulos; B Dillon; M A Chesney; H Tian; N S Hellmann; N I Bandrapalli; L Digilio; B Branson; J O Kahn
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

3.  Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.

Authors:  S Yerly; A Rakik; S K De Loes; B Hirschel; D Descamps; F Brun-Vézinet; L Perrin
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors.

Authors:  M Quigg; S Rebus; A J France; J McMenamin; G Darby; A J Leigh Brown
Journal:  AIDS       Date:  1997-05       Impact factor: 4.177

5.  Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion.

Authors:  S K Brodine; R A Shaffer; M J Starkey; S A Tasker; J L Gilcrest; M K Louder; A Barile; T C VanCott; M T Vahey; F E McCutchan; D L Birx; D D Richman; J R Mascola
Journal:  Ann Intern Med       Date:  1999-10-05       Impact factor: 25.391

6.  Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.

Authors:  P Kosalaraksa; M F Kavlick; V Maroun; R Le; H Mitsuya
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

Authors:  J Goudsmit; A de Ronde; E de Rooij; R de Boer
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Transmission of antiretroviral-drug-resistant HIV-1 variants.

Authors:  S Yerly; L Kaiser; E Race; J P Bru; F Clavel; L Perrin
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

9.  A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

Authors:  K Hertogs; M P de Béthune; V Miller; T Ivens; P Schel; A Van Cauwenberge; C Van Den Eynde; V Van Gerwen; H Azijn; M Van Houtte; F Peeters; S Staszewski; M Conant; S Bloor; S Kemp; B Larder; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

10.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.

Authors:  R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more
  46 in total

Review 1.  A fossil record of zidovudine resistance in transmitted isolates of HIV-1.

Authors:  D R Kuritzkes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Intrapatient escape in the A*0201-restricted epitope SLYNTVATL drives evolution of human immunodeficiency virus type 1 at the population level.

Authors:  Charles T T Edwards; Katja J Pfafferott; Philip J R Goulder; Rodney E Phillips; Edward C Holmes
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

4.  Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.

Authors:  Robert W Shafer; Dong Phuong Nguyen; W Jeffrey Fessel
Journal:  MedGenMed       Date:  2006-08-07

Review 5.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

7.  Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Sarah Palmer; Frank Maldarelli; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-19       Impact factor: 11.205

8.  Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.

Authors:  Maria Mercedes Santoro; Massimo Ciccozzi; Claudia Alteri; Stefania Montieri; Ivailo Alexiev; Iordanka Dimova; Francesca Ceccherini-Silberstein; Danail Beshkov; Giovanni Rezza; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

Review 9.  Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Authors:  Nila Bhana; Douglas Ormrod; Caroline M Perry; David P Figgitt
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.

Authors:  Luis M F Gonzalez; Rodrigo M Brindeiro; Renato S Aguiar; Helena S Pereira; Celina M Abreu; Marcelo A Soares; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.